

**Supplementary Table 1 Survival results**

	Median (months)	95%CI	P
<b>Overall survival (OS)</b>			
Total population	28.00	2.94-53.06	
Subgroup: With vascular invasion	Not reached		0.343
Subgroup: Without vascular invasion	28.00		
Subgroup: Immunotherapy prior	28.00		0.171
Subgroup: Immunotherapy after	Not reached		
Subgroup: Prior TACE	Not reached		0.718
Subgroup: No prior TACE	28.00	2.85 ~ 53.14	
Subgroup: Concomitant target therapy	28.00	2.92 ~ 53.07	0.757
Subgroup: No concomitant target therapy	Not reached		
Subgroup: First-line immunotherapy	28.00	28.00-NA	0.172
Subgroup: Second/third-line immunotherapy	Not reached		
<b>Progression-free survival (PFS)</b>			
Total population	14.00	6.78-21.22	
Subgroup: With vascular invasion	14.00	4.07-23.93	0.584
Subgroup: Without vascular invasion	Not reached		
Subgroup: Immunotherapy prior	9.00	4.76-13.24	0.153
Subgroup: Immunotherapy after	18.00	10.84-25.16	

Subgroup: Prior TACE	Not reached		0.554
Subgroup: No prior TACE	9.00	1.76 ~ 16.23	
Subgroup: Concomitant target therapy	9.00	2.19 ~ 15.80	0.154
Subgroup: No concomitant target therapy	Not reached		
Subgroup: First-line immunotherapy	18.00	6.31 ~ 29.69	0.006
Subgroup: Second/third-line immunotherapy	6.00	0.56 ~ 11.43	

---

TACE: Transarterial chemoembolization; CI: Confidence interval.